Hospira highlights positive data in third quarter

Hospira has published its financial report for the third quarter of 2010, during which the company accomplished a number of key business goals despite "difficult" conditions.

The company was able to generate $949.3 million (596.8 million pounds) in net sales during a quarter which saw it increase investment in research and development programmes and clinical trials.

Christopher Begley, Hospira's chairman and chief executive officer, said the firm has seen encouraging momentum for its newly-launched pharmaceutical products, as well as several existing ones.

He also highlighted the successful implementation of Project Fuel, Hospira's company-wide optimisation and efficiency improvement programme.

Mr Begley said: "We believe the efforts and advancements we are making this year position Hospira for another good year and continued growth going forward."

Earlier this month, Hospira's malignant pleural mesothelioma treatment Tomudex was given an endorsement from a number of leading medical experts during a European Society for Medical Oncology symposium sponsored by the company.